People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
Weight-loss medications are back in the headlines. In particular, Novo Nordisk (NYSE: NVO) stands to gain tremendously as the maker of instant-classic obesity therapy Wegovy as well as the type 2 diabetes treatment Ozempic.
High prescription medicine costs are doubtlessly a major impediment to reaching as much of the weight loss market as possible. But, according to the company's senior leadership, that shouldn't be much of a barrier for Wegovy specifically. Here's why.
Amid what commentators rightly describe as an "insatiable" appetite for type 2 diabetes and weight loss therapies like Ozempic and Wegovy, Novo Nordisk, as well as its prime competitor in the space, Eli Lilly, expect to continue struggling to manufacture enough doses to meet demand for their star medicines for at least another year or so.
Source Fool.com
